ZURICH (Reuters) - Pharmaceuticals giant Novartis is pinning its hopes on a 43-year-old Harvard cancer research star to help fill gaps in its immuno-oncology arsenal after "missing the boat" on some promising therapies.
THE WORLD DOESN'T CARE ABOUT BLINCYTO OR TVEC. LOOK AT THE SALES!
THERE ARE NO MORE SUPPORTIVE CARE DRUGS AMGEN!!! YOU WILL NEVER UN-SEAT GENENTECH, CELGENE, BMS, OR EVEN BE ON PAR WITH 2ND TIER ONCOLOGY LIKE BAYER, PFIZER, NOVARTIS, OR EVEN ABBVIE. YOU CAN DREAM ALL YOU WANT, BUT THAT'S ALL IT WILL EVER BE.
THE WORLD DOESN'T CARE ABOUT BLINCYTO OR TVEC. LOOK AT THE SALES!
THERE ARE NO MORE SUPPORTIVE CARE DRUGS AMGEN!!! YOU WILL NEVER UN-SEAT GENENTECH, CELGENE, BMS, OR EVEN BE ON PAR WITH 2ND TIER ONCOLOGY LIKE BAYER, PFIZER, NOVARTIS, OR EVEN ABBVIE. YOU CAN DREAM ALL YOU WANT, BUT THAT'S ALL IT WILL EVER BE.